Microgen, Fixed-Phage Limited and MICREOS are Dominating the Europe Bacteriophages Therapy Market in 2021

Europe Bacteriophages Therapy Market is expected to grow with a CAGR of 5.1% in the forecast period of 2021 to 2028. The years considered for the study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/europe-bacteriophages-therapy-market

Europe bacteriophages therapy market is a highly consolidated market, which includes a specific number of key players. The market has witnessed increased strategic developments owing to favorable market scenarios.   

The major players dealing in the Europe bacteriophages therapy market are introducing a strong range of products provider along with launching new products and adopting strategic initiatives such as acquisition, agreement, business expansion, award, and recognition into the market. This helped companies to maximize sales with an enhanced product portfolio.

For instance:

  • In October 2018, Microgen announced that Russian Bacteriophages are used in the prevention of emergency infections. The company further added that over 3,000 products had been delivered to the Kuban. This has helped the company to earn more revenue.

Microgen is the dominating player in the Europe bacteriophages therapy market. The other key players existing in the market are, Phagelux Inc., Intralytix, Armata Pharmaceuticals Inc., Locus Biosciences Inc., Pherecydes Pharma, intoDeWorld Inc., Enbiotix, Fixed-Phase Limited, MICREOS, among others.

Europe Bacteriophages Therapy MarketMicrogen

Microgen headquarter is in Russia, Europe, founded in 2003. The company focuses on developing highly effective preparations for healthcare by creating competitive production units in the sphere of biotechnology. The company has wide product categories such as vaccines, allergens, anatoxins, toxins, bacteriophages, immunomodulators, interferons, blood products, sera, culture media, medical devices for diagnostics in vitro, other products, among others in which bacteriophages is the market-focused category. The company is attaining lucrative growth through several strategic initiatives.

For instance,

  • In April 2018, Microgen announced that they had developed a universal drug product that permits one capsule to replace the intake of a complex of traditional antimicrobial agents for infectious diseases treatment. The drug attacks only bacterial cells without affecting the body flora. This has helped the company to enhance its reputation for quality and to reduce the cost of competitiveness

The company has a wide presence across Europe.

Fixed-Phage limited

Fixed-Phage Limited was founded in 2010 in Glasgow, U.K.. The company is focused on inscribing the bacterial challenges by designing, developing and commercializing stabilized phages. The company has wide product categories such Animal Health, Harvest Health, Personal Health, Human Health, Process Health in which Personal Health, Human Health is the market-focused product. The company is attaining lucrative growth through several strategic initiatives.  

  • In March, Fixed-Phage Limited announced that the company has accelerated Fixed Phage fight against damaging bacteria. The company further added that they have received a financial help worth USD 286.08 million from its investors. This has helped the company to accelerate the research without facing any financial barrier

The company has a wide presence across U.K.

MICROES

MICROES is headquartered in The Hague, The Netherlands and was founded in 2005. The company is focused on spearheading this exciting new fields. The company has various product categories that are Human Health, Food Safety, Agriculture, Animal Health in which Food Safety is the market focused product. The company is attaining lucrative growth through several strategic initiatives.

For instance,

  • In March 2019, MICROES announced that the company has secured fund worth USD 33.60 million to accelerate the development of its endolysin technology, set to replace antibiotics. This has helped the company to open a new therapeutic window for treatment of chronic inflammatory conditions in the market.

The company has a presence across the The Netherlands